# Pizarra — PT-pseudo_dcd7bf13a6f4 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd7bf13a6f4
Task: 1

Encounter: Urology - outpatient on 25 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 6.77 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.239 ng/mL²
  - PSA velocity: 1.85 ng/mL/yr
  - Prior PSA: 4.3 ng/mL
  - Prostate volume: 28.27 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8536296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.77 ng/mL. PI-RADS 5. PSAD 0.24. Prostate volume 28 mL. csPCa 0.85.

Vitals: weight 80 kg, height 171 cm, BMI 27.4, BP 133/92 mmHg, HR 72 bpm. Smoking: Current smoker (38 pack-yr).

Chief complaint: Evaluation is required given the ascending prostate-specific antigen levels and the recently completed multiparametric MRI.

History: Investigation was initiated for a progressively climbing prostate-specific antigen in this 74-year-old graphic designer. The most recent laboratory draw recorded 6.77 ng/mL, an increase from 2.6 ng/mL back in January 2024. He shares his home with his partner, stays active through twice-weekly tennis sessions, and limits alcohol intake to approximately three units per week. Severe lower urinary tract symptoms dominate his clinical picture, yielding an IPSS of 22, yet he explicitly denies hematuria, pelvic discomfort, or systemic complaints. His surgical history includes a right knee arthroscopy performed half a decade ago, while his blood pressure remains controlled without pharmacological intervention. A substantial smoking history of 38 pack-years is noted. Following a recent routine chest X-ray, he requests written documentation due to mild hearing loss that complicates rapid conversation.

Physical examination: DRE reveals a uniformly smooth gland with no focal induration, asymmetry, or palpable nodules. The subject appears well-nourished and shows no signs of acute distress. Vitals register at a blood pressure of 133/92 mmHg and a heart rate of 72 bpm. Otoscopic evaluation confirms mild bilateral hearing deficits, aligning with his stated difficulty tracking fast-paced dialogue. The remainder of the systemic survey yields unremarkable results.

Patient info: graphic designer; Married; Lives with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 3 units / week; exercise Tennis 2x/week; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.90 +/- 0.03   (95% CI 0.84-0.95)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.03  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.48 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant immediate action?
  - previous_notes (get_previous_notes) -> What is the patient's prior management context and agreed-upon surveillance pathway?

This case hinges on the interpretation of the PI-RADS 5 MRI and the need to confirm the clinical context (prior management) and PSA trajectory before making a biopsy recommendation.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel and parsed record, failing to incorporate the qualitative information from the mpMRI prose, such as the specific PI-RADS 5 score, or the PSA velocity of 1.85 ng/mL/yr.
The prior did not account for the clinical context that the patient is biopsy-naive, which is a key factor in the guideline criterion.
The prior did not weigh the specific PSA density (0.239 ng/mL²) or the high csPCa probability (0.8536296) against the normal DRE.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with high confidence (0.90), but the guideline criterion is based on PI-RADS $\ge 3$, which is met, but the guideline also mentions that biopsy is not always the next step, especially if MRI is positive. The prior does not account for the potential for overdiagnosis given the high csPCa probability.
The prior's high probability might be inflated by the high csPCa probability (0.8536296), which could lead to an unnecessary intervention if the true risk is lower.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant immediate action?
previous_notes - What is the patient's prior management context and agreed-upon surveillance pathway?
laboratory panel - Does the PSA density (0.239 ng/mL²) align with guideline thresholds for risk stratification?
laboratory panel - Does the PSA density (0.239 ng/mL²) align with guideline thresholds for risk stratification?

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS "5" lesion in the left peripheral zone, 12 mm in greatest dimension, with restricted diffusion and focal enhancement. csPCa predicted probability of "0.8536296".
get_psa_trend
PSA trend: [{"date": "Jan 2024", "val": 0.5}, {"date": "May 2024", "val": 4.0}, {"date": "Oct 2024", "val": 1.5}, {"date": "Feb 2025", "val": 6.77}]
get_previous_notes
Previous notes: Notes from 04 Sep 2023 noted persistent LUTS (IPSS 22) and a PSA of 3.8 ng/mL, leading to a urology referral. Notes from 08 Mar 2023 noted a PSA of 2.9 ng/mL and a plan for a follow-up blood draw later in the year.

NOT RETRIEVED
laboratory panel
Left closed because the moderator's agenda did not explicitly require the full laboratory panel, and the retrieved documents did not raise a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS "5" lesion in the left peripheral zone.
- PSA trend: Significant rise from 1.5 ng/mL (Oct 2024) to 6.77 ng/mL (Feb 2025).
- Previous notes: Patient was referred for ascending PSA and was on a monitoring protocol.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the high-risk PI-RADS 5 MRI finding and the significant, recent rise in PSA velocity.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The evidence retrieved strongly supports biopsy based on the PI-RADS 5 MRI and significant PSA trend, satisfying the guideline criterion. The laboratory panel remains unretrieved, but the core decision point is addressed.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The guideline criterion mandates biopsy for a PI-RADS 5 lesion, which was retrieved from the MRI report. This finding was reinforced by the significant PSA trend, showing a rise from 1.5 ng/mL to 6.77 ng/mL. The statistical prior also suggested biopsy with high confidence, and the retrieved evidence confirmed the clinical indication.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
